Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (Q33338529)

25 July 2017

1 reference

title

Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (English)

1 reference

25 July 2017

1 reference

1 reference

acute coronary syndrome

1 reference

heparin-induced thrombocytopenia

inferred from title

1 reference

Mahaffey KW

1

1 reference

25 July 2017

publication date

1 September 2001

1 reference

Current cardiology reports

25 July 2017

published in

1 reference

25 July 2017

volume

3

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

362-370

1 reference

Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-001-0052-7

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

21 January 2018

1 reference

12 December 2020

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance

1 reference

12 December 2020

Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia

1 reference

12 December 2020

Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

1 reference

12 December 2020

Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Heparin-induced thrombocytopenia and thrombosis

1 reference

12 December 2020

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

12 December 2020

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

1 reference

12 December 2020

Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia

1 reference

12 December 2020

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

1 reference

12 December 2020

Heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin-Induced Thrombocytopenia

1 reference

12 December 2020

Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod

1 reference

12 December 2020

Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets

1 reference

12 December 2020

Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.

1 reference

12 December 2020

Platelet alpha-granule proteins: studies on release and subcellular localization

1 reference

12 December 2020

Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients

1 reference

12 December 2020

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

12 December 2020

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

1 reference

12 December 2020

Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia

1 reference

12 December 2020

Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).

1 reference

12 December 2020

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

1 reference

12 December 2020

Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia

1 reference

12 December 2020

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

12 December 2020

Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation

1 reference

12 December 2020

Thrombin inhibition by hirudin: how hirudin inhibits thrombin

1 reference

12 December 2020

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

12 December 2020

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

1 reference

12 December 2020

Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Anti-platelet antibody interactions with Fc gamma receptor.

1 reference

12 December 2020

Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.

1 reference

12 December 2020

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group

1 reference

12 December 2020

Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.

1 reference

12 December 2020

Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets

1 reference

12 December 2020

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia

1 reference

12 December 2020

10.1007/S11886-001-0052-7

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1043408559

0 references

Fatcat ID

release_h2dmdcnz7zf7lb4den5p76inji

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h2dmdcnz7zf7lb4den5p76inji

24 November 2022

mapped directly with Wikidata item

1 reference